Your browser doesn't support javascript.
loading
NRF2 drives an oxidative stress response predictive of breast cancer.
Wolowczyk, Camilla; Neckmann, Ulrike; Aure, Miriam Ragle; Hall, Martina; Johannessen, Bjarne; Zhao, Sen; Skotheim, Rolf I; Andersen, Sonja B; Zwiggelaar, Rosalie; Steigedal, Tonje S; Lingjærde, Ole Christian; Sahlberg, Kristine Kleivi; Almaas, Eivind; Bjørkøy, Geir.
Afiliação
  • Wolowczyk C; Centre of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian Universi
  • Neckmann U; Centre of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian Universi
  • Aure MR; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Hall M; Department of Biotechnology and Food Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, Trondheim, Norway; K.G.Jebsen Center for Genetic Epidemiology, Department of Public Health and General Practice, Faculty of Medicine and Health Sciences, Norwegian University of
  • Johannessen B; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Norwegian Cancer Genomics Consortium, Oslo, Norway.
  • Zhao S; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Norwegian Cancer Genomics Consortium, Oslo, Norway.
  • Skotheim RI; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway; Norwegian Cancer Genomics Consortium, Oslo, Norway.
  • Andersen SB; Centre of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian Universi
  • Zwiggelaar R; Centre of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
  • Steigedal TS; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Lingjærde OC; Department of Computer Science, University of Oslo, Oslo, Norway.
  • Sahlberg KK; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Department of Research, Vestre Viken Hospital Trust, Drammen, Norway.
  • Almaas E; Department of Biotechnology and Food Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, Trondheim, Norway; K.G.Jebsen Center for Genetic Epidemiology, Department of Public Health and General Practice, Faculty of Medicine and Health Sciences, Norwegian University of
  • Bjørkøy G; Centre of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian Universi
Free Radic Biol Med ; 184: 170-184, 2022 05 01.
Article em En | MEDLINE | ID: mdl-35381325
ABSTRACT
Many breast cancer patients are diagnosed with small, well-differentiated, hormone receptor-positive tumors. Risk of relapse is not easily identified in these patients, resulting in overtreatment. To identify metastasis-related gene expression patterns, we compared the transcriptomes of the non-metastatic 67NR and metastatic 66cl4 cell lines from the murine 4T1 mammary tumor model. The transcription factor nuclear factor, erythroid 2-like 2 (NRF2, encoded by NFE2L2) was constitutively activated in the metastatic cells and tumors, and correspondingly a subset of established NRF2-regulated genes was also upregulated. Depletion of NRF2 increased basal levels of reactive oxygen species (ROS) and severely reduced ability to form primary tumors and lung metastases. Consistently, a set of NRF2-controlled genes was elevated in breast cancer biopsies. Sixteen of these were combined into a gene expression signature that significantly improves the PAM50 ROR score, and is an independent, strong predictor of prognosis, even in hormone receptor-positive tumors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Fator 2 Relacionado a NF-E2 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Fator 2 Relacionado a NF-E2 Idioma: En Ano de publicação: 2022 Tipo de documento: Article